Navneet Omprakash Soni*
Centre for Research in Molecular Pharmacology,
Shramik coloney, Laxminagar, Sangli Maharashtra, India
*Address for Correspondence: Dr. Navneet
Omprakash Soni, Research scholar, Department of Pharmacology, Centre for Research
in Molecular Pharmacology, Maharashtra, India
ABSTRACT- Transient Receptor Potential Canonical (TRPC6) assumes vital part in
pathophysiology of DN and is up-regulated
by angiotensin II, high glucose level, Transforming growth factor beta (TGFβ),
and intercede podocyte damage in Diabetes Mellitus focusing on TRPC6 may reduce
podocyte damage and proteinuria. From different investigation and proof gave by
analyst and author work on
pathophysiological part of TRPC 6 and the medications which modify or restrain
TRPC6 or its downstream molecular target propose that TRPC6 is novel molecular
target. Recently distinguished ROS/TRPC6 pathway will cover the best approach
to new, reassuring restorative systems to target kidney ailments, especially
Diabetic Nephropathy.
Key-words- Diabetic nephropathy, TRPC6, Podocyte Injury, Proteinuria
